Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: Extended analysis of the PROSE trial

Published 2015 View Full Article

Authors

Keywords

Non-small cell lung cancer, Erlotinib, Proteomic test, Economics, Cost-effectiveness, Chemotherapy

Journal

LUNG CANCER

Volume 88, Issue 2, Pages 223-230

Publisher

Elsevier BV

Online

2015-03-12

DOI

10.1016/j.lungcan.2015.03.006

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started